GGrantIndex
Sort

40,608 grants matching prostate cancer

Functional Analysis of Distinct and Co-existing Transcriptional Programs Regulating Tumor Dormancy

$384,300
Maria Sosa · Albert Einstein College Of Medicine · R01 · FY2023 · CA

Functional Analysis of Distinct and Co-existing Transcriptional Programs Regulating Tumor Dormancy

$384,300
Maria Sosa · Albert Einstein College Of Medicine · R01 · FY2025 · CA

High-throughput palmitoyl-proteomics profiling of extracellular vesicles for identification of biomarkers for early detection of clinically significant prostate cancer

$384,283
Dolores Di Vizio · Cedars-Sinai Medical Center · R01 · FY2018 · CA

Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition

$384,278
Zachary Scott Morris · University Of Wisconsin-Madison · P01 · FY2022 · CA

Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition

$384,278
Zachary Scott Morris · University Of Wisconsin-Madison · P01 · FY2023 · CA

Hyperpolarized 13c NMR Studies of Prostate Cancer (RMI)

$384,258
John Kurhanewicz · University Of California, San Francisco · R21 · FY2007 · EB

Targeting cytoplasmic SET oncoprotein by sphingolipid analog drugs for the induction of necroptosis to treat lung cancer

$384,227
Besim Ogretmen · Medical University Of South Carolina · R01 · FY2024 · CA

Role of immune cell OGR1 in prostate cancer development and the mechanisms involv

$384,136
Yan Xu · Indiana University Indianapolis · R01 · FY2013 · CA

Transcription Dynamics in Single Cells

$384,127
Daniel Larson · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA

The Fibrosis-Lymphedema Continuum in Head and Neck Cancer

$384,109
Sheila H Ridner · Vanderbilt University · R01 · FY2013 · CA

Androgen Signaling in CaP with loss of MAP3K7 and CHD1

$384,104
Scott D Cramer · University Of Colorado Denver · R01 · FY2023 · CA

Androgen Signaling in CaP with loss of MAP3K7 and CHD1

$384,104
Scott D Cramer · University Of Colorado Denver · R01 · FY2022 · CA

GENE-ENVIRONMENT INTERACTION IN PROSTATE CANCER

$384,097
Henry Ford Health System · R01 · FY2002 · ES

Methods and Tools for Integrating Pathomics Data into Cancer Registries

$384,048
Joel H Saltz · State University New York Stony Brook · UG3 · FY2019 · CA

Macrophages induce a tumor-promoting stable EMT in prostate cancer

$384,035
Kenneth J. Pienta · University Of Michigan At Ann Arbor · P01 · FY2016 · CA

IGF-I LEVELS, IGF-I GENOTYPE, AND PROSTATE CANCER

$384,028
Fred Hutchinson Cancer Research Center · R01 · FY2001 · CA

Targeting Drug-Resistant Castration Resistant Prostate Cancer via LIMK2

$384,026
Kavita Shah · Purdue University · R01 · FY2023 · CA

ANDROGEN RECEPTOR AND PROSTATE CANCER RISK IN CHINESE

$383,993
University Of Southern California · R01 · FY2000 · CA

Phase I Clinical Trials of Novel Agents

$383,985
Sloan-Kettering Institute For Cancer Res · U01 · FY2003 · CA

Reduced-Order Constrained Optimization for Rapid IMRT and VMAT Treatment Planning

$383,930
Richard J Radke · Rensselaer Polytechnic Institute · R01 · FY2012 · CA

Characterizing the signaling pathways that regulate Skp2 oncogenic function

$383,865
Wenyi Wei · Beth Israel Deaconess Medical Center · R01 · FY2019 · CA

Pure Flavonolignans from S. marianum in Prostate Cancer

$383,850
David J Kroll · Research Triangle Institute · R01 · FY2006 · CA

Requirements for Normal Rb Function In Vivo

$383,842
David W Goodrich · Roswell Park Cancer Institute Corp · R01 · FY2009 · CA

Investigating Correlates and Therapeutics of Fatigue in Cancer Patients

$383,837
Leorey Saligan · National Institute Of Nursing Research · ZIA · FY2014 · NR

Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy

$383,789
David Gius · University Of Texas Hlth Science Center · R01 · FY2025 · CA